Nothing Special   »   [go: up one dir, main page]

EA201390725A1 - Молчащие fc-варианты анти-cd40 антител - Google Patents

Молчащие fc-варианты анти-cd40 антител

Info

Publication number
EA201390725A1
EA201390725A1 EA201390725A EA201390725A EA201390725A1 EA 201390725 A1 EA201390725 A1 EA 201390725A1 EA 201390725 A EA201390725 A EA 201390725A EA 201390725 A EA201390725 A EA 201390725A EA 201390725 A1 EA201390725 A1 EA 201390725A1
Authority
EA
Eurasian Patent Office
Prior art keywords
silent
options
antibody
antibodies
disorders
Prior art date
Application number
EA201390725A
Other languages
English (en)
Other versions
EA026133B1 (ru
Inventor
Кристоф Хойссер
Джеймс Раш
Карен Винсент
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44925566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390725(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201390725A1 publication Critical patent/EA201390725A1/ru
Publication of EA026133B1 publication Critical patent/EA026133B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Настоящее изобретение относится к молчащим Fc-вариантам анти-CD40 антител и композициям и методам использования указанных антител для лечения патологических нарушений, таких как аутоиммунные и воспалительные нарушения, и/или для предотвращения или снижения риска отторжения трансплантата при трансплантации.
EA201390725A 2010-11-15 2011-11-14 МОЛЧАЩИЕ Fc-ВАРИАНТЫ АНТИ-CD40 АНТИТЕЛ EA026133B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41356710P 2010-11-15 2010-11-15
PCT/EP2011/070058 WO2012065950A1 (en) 2010-11-15 2011-11-14 Silent fc variants of anti-cd40 antibodies

Publications (2)

Publication Number Publication Date
EA201390725A1 true EA201390725A1 (ru) 2013-09-30
EA026133B1 EA026133B1 (ru) 2017-03-31

Family

ID=44925566

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390725A EA026133B1 (ru) 2010-11-15 2011-11-14 МОЛЧАЩИЕ Fc-ВАРИАНТЫ АНТИ-CD40 АНТИТЕЛ

Country Status (38)

Country Link
US (8) US8828396B2 (ru)
EP (4) EP4023676A1 (ru)
JP (1) JP5782132B2 (ru)
KR (1) KR101632775B1 (ru)
CN (2) CN103209996B (ru)
AR (2) AR083847A1 (ru)
AU (1) AU2011331288B2 (ru)
BR (1) BR112013011644B1 (ru)
CA (1) CA2815921C (ru)
CL (1) CL2013001124A1 (ru)
CO (1) CO6801629A2 (ru)
CR (1) CR20130222A (ru)
CU (1) CU24057B1 (ru)
CY (1) CY1119097T1 (ru)
DK (2) DK2640749T3 (ru)
EA (1) EA026133B1 (ru)
ES (2) ES2633817T3 (ru)
GT (1) GT201300128A (ru)
HR (2) HRP20220413T1 (ru)
HU (2) HUE034203T2 (ru)
IL (1) IL225719A (ru)
JO (1) JO3266B1 (ru)
LT (2) LT2640749T (ru)
MA (1) MA34654B1 (ru)
MX (1) MX336633B (ru)
MY (1) MY159316A (ru)
NZ (1) NZ609549A (ru)
PE (1) PE20140979A1 (ru)
PL (2) PL3502138T3 (ru)
PT (2) PT2640749T (ru)
RS (2) RS63094B1 (ru)
SG (1) SG189928A1 (ru)
SI (2) SI2640749T1 (ru)
TW (2) TWI608016B (ru)
UA (1) UA112417C2 (ru)
UY (2) UY39292A (ru)
WO (1) WO2012065950A1 (ru)
ZA (1) ZA201302532B (ru)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153526B1 (en) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP2676677B1 (en) * 2011-02-17 2019-05-22 Kyowa Hakko Kirin Co., Ltd. Highly concentrated anti-cd40 antibody pharmaceutical preparation
EP2683406B1 (en) 2011-03-11 2019-05-08 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
RS57087B1 (sr) 2011-04-21 2018-06-29 Bristol Myers Squibb Co Polipeptidi antitela koji antagonizuju cd40
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
EP2766395B1 (en) 2011-10-13 2019-11-20 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40l
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
EP3925977A1 (en) 2012-10-30 2021-12-22 Apexigen, Inc. Anti-cd40 antibodies and methods of use
CA2903772A1 (en) 2013-03-15 2014-09-25 Novartis Ag Antibody drug conjugates
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
BR112017001588A2 (pt) 2014-08-12 2017-11-21 Novartis Ag conjugados de anticorpo/fármaco anti-cdh6
MX2017004691A (es) 2014-10-10 2017-10-02 Innate Pharma Bloqueo de cd73.
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
GB201501613D0 (en) 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
DK3303395T3 (da) 2015-05-29 2020-01-27 Abbvie Inc Anti-cd40-antistoffer og anvendelser deraf
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
CN107969127B (zh) * 2015-09-08 2022-09-06 赛瑞品股份有限公司 Apoa-1融合多肽及相关组合物和方法
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
MY196646A (en) * 2015-09-30 2023-04-27 Janssen Biotech Inc Agonistic Antibodies Specifically Binding Human CD40 And Methods of use
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
JP7132123B2 (ja) 2016-02-10 2022-09-06 ノバルティス アーゲー 原発性シェーグレン症候群の治療のためのｐｉ３ｋの活性阻害剤または機能阻害剤の使用
EP3426688A1 (en) 2016-03-08 2019-01-16 Innate Pharma Siglec neutralizing antibodies
EP3429692A1 (en) 2016-03-14 2019-01-23 Innate Pharma Anti-cd39 antibodies
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
WO2018083080A2 (en) 2016-11-04 2018-05-11 Innate Pharma Nkp46 ligand
CA3044526A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018138032A2 (en) 2017-01-24 2018-08-02 Innate Pharma NKp46 BINDING AGENTS
WO2018141959A1 (en) 2017-02-06 2018-08-09 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
EP3600233A4 (en) * 2017-03-26 2020-10-21 Stafford, Vivi, Robyn METHOD OF TREATMENT OF SKIN DISEASES OF THE EYELIDS
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
CN110621697B (zh) 2017-05-25 2023-06-27 百时美施贵宝公司 拮抗性cd40单克隆抗体及其用途
WO2018217988A1 (en) * 2017-05-25 2018-11-29 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
TW201902462A (zh) * 2017-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 用於免疫促效劑之新穎投與途徑
JP7293188B2 (ja) 2017-07-10 2023-06-19 イナート・ファルマ・ソシエテ・アノニム Ｓｉｇｌｅｃ－９中和抗体
AU2018298673A1 (en) 2017-07-10 2019-12-19 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
CN117551197A (zh) * 2017-09-19 2024-02-13 Mab发现股份有限公司 激动性cd40抗体
MX2020004411A (es) * 2017-11-03 2020-08-06 Novartis Ag Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
WO2019106578A2 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
BR112020020277A2 (pt) * 2018-04-13 2021-01-19 Novartis Ag Anticorpos anti-cd40 para uso na prevenção de rejeição de enxerto
IT201800004853A1 (it) 2018-04-24 2019-10-24 Metodi per trattare il cancro
JP7490574B2 (ja) 2018-05-31 2024-05-27 ノバルティス アーゲー Ｂ型肝炎抗体
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US11377503B2 (en) 2018-06-18 2022-07-05 Innate Pharma Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
EP3902829A2 (en) 2018-12-26 2021-11-03 Innate Pharma Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
KR20210114964A (ko) 2019-01-11 2021-09-24 노파르티스 아게 화농성 한선염 치료에 사용하기 위한 항-cd40 항체
KR20220002959A (ko) 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. Cd73 차단 항체
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
US20220195061A1 (en) 2019-05-08 2022-06-23 Novartis Ag Anti-cd40 antibodies for use in treatment of tidm and insulitis
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
JP7520893B2 (ja) 2019-06-12 2024-07-23 ノバルティス アーゲー ナトリウム利尿ペプチド受容体１抗体及び使用方法
MX2022000133A (es) * 2019-07-01 2022-04-27 Tonix Pharma Ltd Anticuerpos anti-cd154 y usos de los mismos.
MX2022003009A (es) * 2019-09-11 2022-06-14 Novartis Ag Metodo para prevenir trastornos asociados a virus humanos en pacientes.
EP4031566A1 (en) 2019-09-18 2022-07-27 Novartis AG Nkg2d fusion proteins and uses thereof
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023512286A (ja) * 2020-01-31 2023-03-24 サノフイ 抗体の肺送達
WO2021173985A2 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
WO2022006179A1 (en) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
KR20230050378A (ko) 2020-08-13 2023-04-14 이나뜨 파르마 에스.에이. 항-cd73 항체를 사용하여 암을 치료하는 방법
JP2023538105A (ja) * 2020-08-21 2023-09-06 ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド Ｃｄ４０アゴニスト抗体及び使用方法
AU2021329404A1 (en) 2020-08-21 2023-04-20 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
JP2024523514A (ja) * 2021-06-28 2024-06-28 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ４０抗体、その抗原結合断片及び医薬用途
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN117858901A (zh) 2021-08-20 2024-04-09 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
WO2023025248A1 (zh) 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
CN118234749A (zh) 2021-09-17 2024-06-21 诺华股份有限公司 用于预防异种移植中的移植物排斥的方法
WO2023046037A1 (zh) 2021-09-24 2023-03-30 正大天晴药业集团股份有限公司 抗cd40抗体及其用途
CN118139886A (zh) 2021-10-01 2024-06-04 Mab发现股份有限公司 作为免疫刺激剂的激动性cd40抗体
TW202405009A (zh) 2022-03-30 2024-02-01 瑞士商諾華公司 使用抗利尿鈉肽受體１（ｎｐｒ１）抗體治療障礙之方法
TW202423983A (zh) 2022-09-15 2024-06-16 瑞士商諾華公司 使用嵌合抗原受體療法的自體免疫性障礙的治療
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024107752A2 (en) 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024140917A1 (zh) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 抗cd40抗体药物偶联物、其制备方法及其医药用途
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106A (en) 1915-08-24 Specipication
US4766A (en) 1846-09-19 Stbaw-cutter
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
CA2172376C (en) 1993-10-01 2008-11-18 William C. Fanslow, Iii Antibodies to cd40
JPH09507074A (ja) 1993-12-23 1997-07-15 イミュネックス・コーポレーション Ｃｄ４０を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
EP0750458B1 (en) 1994-03-03 2003-08-27 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc., San Francisco Stabilisierte antikörperformulierung
KR100567998B1 (ko) 1997-06-20 2006-04-07 바이오겐 아이덱 엠에이 인코포레이티드 치료용 단백질 저해제 증후군에 대한 ｃｄ154 차단 요법
DE59805732D1 (de) 1997-09-23 2002-10-31 Rentschler Biotech Gmbh Flüssige interferon-beta-formulierungen
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
AU1590201A (en) 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU6461201A (en) 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
JP2004508420A (ja) 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
DE60119945T2 (de) 2000-10-02 2007-01-18 Chiron Corp., Emeryville VERFAHREN ZUR THERAPIE VON B-ZELLMALIGNITÄTEN UNTER VERWENDUNG VON ANTAGONISTISCHEN ANTI-CD40-Antikörpern
CA2436180C (en) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
CA2440831C (en) 2001-04-02 2013-05-28 Genentech, Inc. Combination therapy using cd40 and cd20 ligands
ATE374214T1 (de) 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2466931A1 (en) 2001-11-26 2003-06-05 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
EP3417875B1 (en) 2003-02-10 2020-06-17 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
DK1694360T3 (da) 2003-11-04 2010-10-18 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-antistoffer til behandling af autoimmune og inflammatoriske sygdomme og organtransplantationafstødning
ATE474599T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP1684869B1 (en) 2003-11-04 2011-07-20 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for b cell-related cancers
PT1680141E (pt) 2003-11-04 2010-12-20 Novartis Vaccines & Diagnostic Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40
PT1682177E (pt) 2003-11-04 2010-11-29 Xoma Technology Lt Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica
PT1707627E (pt) 2003-12-25 2013-01-24 Kyowa Hakko Kirin Co Ltd Mutante antagonista de anticorpo anti-cd40
CN101014386A (zh) 2004-04-27 2007-08-08 诺华疫苗和诊断公司 拮抗性抗－cd40单克隆抗体及其使用方法
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
AU2006247134B2 (en) 2005-05-18 2012-05-10 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
CA2627891A1 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
CN101374865A (zh) * 2005-12-16 2009-02-25 健泰科生物技术公司 抗ox40l抗体及其使用方法
MX2008013508A (es) 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
KR20090027227A (ko) * 2006-06-06 2009-03-16 제넨테크, 인크. 항-ｄｌｌ4 항체 및 이의 사용 방법
DK2550972T3 (en) * 2007-04-02 2018-04-23 Genentech Inc otho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
CN101711286A (zh) * 2007-04-02 2010-05-19 健泰科生物技术公司 预示类风湿性关节炎对b细胞拮抗剂的响应的生物学标志物
EP2176298B1 (en) * 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
SI4209510T1 (sl) * 2008-12-09 2024-04-30 F. Hoffmann-La Roche Ag Protitelesa anti-PD-L1 in njihova uporaba za izboljšanje funkcije celic T
CA2759146C (en) * 2009-04-20 2017-06-13 Kyowa Hakko Kirin Co., Ltd. Agonist anti-cd40 antibody
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AU2014231345B2 (en) 2013-03-15 2019-01-17 Synaptive Medical Inc. Intelligent positioning system and methods therefore

Also Published As

Publication number Publication date
EP4023676A1 (en) 2022-07-06
NZ609549A (en) 2015-05-29
US20240228640A9 (en) 2024-07-11
HRP20220413T1 (hr) 2022-05-27
SI3502138T1 (sl) 2022-05-31
TWI608016B (zh) 2017-12-11
DK3502138T3 (da) 2022-04-19
TWI531581B (zh) 2016-05-01
CN103209996A (zh) 2013-07-17
US20180118843A1 (en) 2018-05-03
US10323096B2 (en) 2019-06-18
UY39292A (es) 2021-07-30
ES2911460T3 (es) 2022-05-19
JP2014500720A (ja) 2014-01-16
RS56153B1 (sr) 2017-11-30
SG189928A1 (en) 2013-06-28
AU2011331288A1 (en) 2013-05-02
US20200087409A1 (en) 2020-03-19
EP2640749B1 (en) 2017-04-19
BR112013011644B1 (pt) 2022-02-22
HUE058015T2 (hu) 2022-06-28
US20140341898A1 (en) 2014-11-20
BR112013011644A2 (pt) 2016-08-02
UA112417C2 (uk) 2016-09-12
US20120121585A1 (en) 2012-05-17
HUE034203T2 (en) 2018-01-29
US20160152721A1 (en) 2016-06-02
MX336633B (es) 2016-01-26
EP3222636A1 (en) 2017-09-27
CN103209996B (zh) 2016-07-20
PT3502138T (pt) 2022-04-06
LT2640749T (lt) 2017-07-10
WO2012065950A1 (en) 2012-05-24
CA2815921A1 (en) 2012-05-24
EP3502138B9 (en) 2022-03-09
ES2633817T3 (es) 2017-09-25
CY1119097T1 (el) 2018-01-10
CO6801629A2 (es) 2013-11-29
UY33728A (es) 2012-06-29
KR101632775B1 (ko) 2016-06-22
US20240132606A1 (en) 2024-04-25
EA026133B1 (ru) 2017-03-31
US9828433B2 (en) 2017-11-28
MA34654B1 (fr) 2013-11-02
KR20130080856A (ko) 2013-07-15
US11124578B2 (en) 2021-09-21
CN105949314B (zh) 2021-04-09
CU20130071A7 (es) 2013-09-27
LT3502138T (lt) 2022-04-11
US9688768B2 (en) 2017-06-27
MX2013005477A (es) 2013-06-12
IL225719A (en) 2017-09-28
CR20130222A (es) 2013-06-28
AR083847A1 (es) 2013-03-27
CA2815921C (en) 2021-07-06
JO3266B1 (ar) 2018-09-16
ZA201302532B (en) 2014-09-25
JP5782132B2 (ja) 2015-09-24
SI2640749T1 (sl) 2017-07-31
PL2640749T3 (pl) 2017-09-29
RS63094B1 (sr) 2022-04-29
AR122999A2 (es) 2022-10-19
PT2640749T (pt) 2017-07-25
US20170267772A1 (en) 2017-09-21
DK2640749T3 (en) 2017-07-31
EP3502138A1 (en) 2019-06-26
GT201300128A (es) 2015-06-02
EP2640749A1 (en) 2013-09-25
US20220204635A1 (en) 2022-06-30
HRP20171084T1 (hr) 2017-10-06
AU2011331288B2 (en) 2014-09-11
PL3502138T3 (pl) 2022-05-02
EP3502138B1 (en) 2022-01-19
US9221913B2 (en) 2015-12-29
CN105949314A (zh) 2016-09-21
TW201623335A (zh) 2016-07-01
US8828396B2 (en) 2014-09-09
PE20140979A1 (es) 2014-08-09
CL2013001124A1 (es) 2014-07-04
TW201305208A (zh) 2013-02-01
MY159316A (en) 2016-12-30
IL225719A0 (en) 2013-06-27
CU24057B1 (es) 2014-12-26

Similar Documents

Publication Publication Date Title
EA201390725A1 (ru) Молчащие fc-варианты анти-cd40 антител
CY1123145T1 (el) Anti-cd40 αντισωματα
GB201112429D0 (en) Antigen-binding proteins with increased FcRn binding
MX2013009362A (es) Anticuerpo contra el csf-1r.
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA201490195A1 (ru) Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
EA201391735A1 (ru) Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201891992A1 (ru) Химерные рецепторы и способы их применения
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA200802168A1 (ru) Гуманизированное антитело к с-kit
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201590247A1 (ru) Антитела к siglec-15
EA201391755A1 (ru) Анти-kir антитела для лечения воспалительных заболеваний
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
MX349463B (es) Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
EA201490677A1 (ru) Связывающие антиген cd27l белки
EA201391298A1 (ru) Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител
EA201201016A1 (ru) Антидоты антикоагулянтов

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM